Nemvaleukin alfa

Mural Oncology is discontinuing all clinical development of nemvaleukin alfa after the immunotherapy failed to meet target goals in melanoma and ovarian cancer trials.

Merck is expediting the launch of a subcutaneous formulation of Keytruda, anticipating approval and market availability in 2025, to extend patent protection.

Mural Oncology's ARTISTRY-7 trial evaluating nemvaleukin with pembrolizumab in platinum-resistant ovarian cancer has reached 75% of overall survival events.

Neoadjuvant nivolumab with or without ipilimumab induced immune activation and pathologic complete responses in early triple-negative breast cancer (TNBC).

The European Commission has requested the EMA to re-examine Leqembi's safety data, potentially delaying its EU approval beyond the expected timeframe.